Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.

Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P.

Oncoimmunology. 2015 Mar 16;4(4):e1001217. eCollection 2015 Apr.

2.

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer.

Belani CP, Yamamoto N, Bondarenko IM, Poltoratskiy A, Novello S, Tang J, Bycott P, Niethammer AG, Ingrosso A, Kim S, Scagliotti GV.

BMC Cancer. 2014 Apr 25;14:290. doi: 10.1186/1471-2407-14-290.

3.

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B.

J Clin Oncol. 2014 Mar 10;32(8):752-9. doi: 10.1200/JCO.2013.50.5305. Epub 2013 Dec 2.

PMID:
24297945
4.

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.

Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, Grenacher L, Buchler MW, Koch M, Weitz J, Haefeli WE, Schmitz-Winnenthal FH.

BMC Cancer. 2012 Aug 20;12:361. doi: 10.1186/1471-2407-12-361.

5.

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O.

Clin Cancer Res. 2011 Dec 1;17(23):7462-9. doi: 10.1158/1078-0432.CCR-11-0534. Epub 2011 Oct 5.

6.

Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis.

Xiang R, Luo Y, Niethammer AG, Reisfeld RA.

Immunol Rev. 2008 Apr;222:117-28. doi: 10.1111/j.1600-065X.2008.00613.x. Review.

PMID:
18363997
7.

Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis.

Hauer AD, van Puijvelde GH, Peterse N, de Vos P, van Weel V, van Wanrooij EJ, Biessen EA, Quax PH, Niethammer AG, Reisfeld RA, van Berkel TJ, Kuiper J.

Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):2050-7. Epub 2007 Jun 28.

PMID:
17600223
8.

Potential target antigens for immunotherapy in human pancreatic cancer.

Schmitz-Winnenthal FH, Galindo-Escobedo LV, Rimoldi D, Geng W, Romero P, Koch M, Weitz J, Krempien R, Niethammer AG, Beckhove P, Buchler MW, Z'graggen K.

Cancer Lett. 2007 Jul 18;252(2):290-8. Epub 2007 Feb 22.

PMID:
17320278
9.

Long-term results of intraoperative presacral electron boost radiotherapy (IOERT) in combination with total mesorectal excision (TME) and chemoradiation in patients with locally advanced rectal cancer.

Krempien R, Roeder F, Oertel S, Roebel M, Weitz J, Hensley FW, Timke C, Funk A, Bischof M, Zabel-Du Bois A, Niethammer AG, Eble MJ, Buchler MW, Treiber M, Debus J.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1143-51. Epub 2006 Sep 18.

PMID:
16979835
10.

Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.

Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA.

J Clin Invest. 2006 Jul;116(7):1955-62. Epub 2006 Jun 22. Erratum in: J Clin Invest. 2009 Feb;119(2):421.

11.

Intraoperative electron boost radiation followed by moderate doses of external beam radiotherapy in limb-sparing treatment of patients with extremity soft-tissue sarcoma.

Oertel S, Treiber M, Zahlten-Hinguranage A, Eichin S, Roeder F, Funk A, Hensley FW, Timke C, Niethammer AG, Huber PE, Weitz J, Eble MJ, Buchler MW, Bernd L, Debus J, Krempien RC.

Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1416-23. Epub 2006 Jan 18.

PMID:
16413697
12.

Combination of external-beam radiotherapy with intraoperative electron-beam therapy is effective in incompletely resected pediatric malignancies.

Oertel S, Niethammer AG, Krempien R, Roeder F, Eble MJ, Baer C, Huber PE, Kulozik A, Waag KL, Treiber M, Debus J.

Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):235-41. Epub 2005 Oct 27.

PMID:
16257132
13.

Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.

Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE.

Clin Cancer Res. 2005 Sep 1;11(17):6270-9.

14.

Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy.

Niethammer AG, Wodrich H, Loeffler M, Lode HN, Emmerich K, Abdollahi A, Krempien R, Debus J, Huber PE, Reisfeld RA.

FASEB J. 2005 Jan;19(1):158-9. Epub 2004 Oct 21.

PMID:
15498893
15.

DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis.

Reisfeld RA, Niethammer AG, Luo Y, Xiang R.

Immunol Rev. 2004 Jun;199:181-90. Review.

PMID:
15233734
16.

DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis.

Reisfeld RA, Niethammer AG, Luo Y, Xiang R.

Int Arch Allergy Immunol. 2004 Mar;133(3):295-304. Epub 2004 Feb 25. Review.

PMID:
14988601
17.

Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.

Schroeder U, Bernt KM, Lange B, Wenkel J, Jikai J, Shabat D, Amir R, Huebener N, Niethammer AG, Hagemeier C, Wiebusch L, Gaedicke G, Wrasidlo W, Reisfeld RA, Lode HN.

Blood. 2003 Jul 1;102(1):246-53. Epub 2003 Mar 6.

PMID:
12623853
18.

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.

Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA.

Nat Med. 2002 Dec;8(12):1369-75. Epub 2002 Nov 4.

PMID:
12415261
19.

T cell homeostatic proliferation elicits effective antitumor autoimmunity.

Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN.

J Clin Invest. 2002 Jul;110(2):185-92.

20.

MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma.

Ruehlmann JM, Xiang R, Niethammer AG, Ba Y, Pertl U, Dolman CS, Gillies SD, Reisfeld RA.

Cancer Res. 2001 Dec 1;61(23):8498-503.

21.

An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice.

Niethammer AG, Primus FJ, Xiang R, Dolman CS, Ruehlmann JM, Ba Y, Gillies SD, Reisfeld RA.

Vaccine. 2001 Nov 12;20(3-4):421-9.

PMID:
11672905
22.

A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.

Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Silletti S, Lode HN, Dolman CS, Gillies SD, Reisfeld RA.

J Immunol. 2001 Oct 15;167(8):4560-5.

23.

Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.

Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA.

Cancer Res. 2001 Aug 15;61(16):6178-84.

24.

Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice.

Xiang R, Silletti S, Lode HN, Dolman CS, Ruehlmann JM, Niethammer AG, Pertl U, Gillies SD, Primus FJ, Reisfeld RA.

Clin Cancer Res. 2001 Mar;7(3 Suppl):856s-864s.

PMID:
11300483
25.

Use of the platelet histogram maximum in evaluating thrombocytopenia.

Niethammer AG, Forman EN.

Am J Hematol. 1999 Jan;60(1):19-23.

Supplemental Content

Loading ...
Support Center